Where Recursion Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. The analysts have an average price target of $18.5 versus the current price of $12.08, implying an upside. This current average represents a 14.63% decrease from the previous average price target of $21.67.
July 13, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on Recursion Pharmaceuticals with an average price target of $18.5, implying an upside from the current price.
The bullish outlook from analysts indicates a positive sentiment towards the stock. The average price target of $18.5 is higher than the current price, suggesting an upside potential. However, the decrease in the average price target from the previous one might indicate a reduced optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100